Obesity Management

Drugs like semaglutide are able to treat both diabetes and obesity.

A discussion into available pharmacotherapy for obesity and the uptake in practice of newer agents.

Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.

Type 2 diabetes can be more aggressive in younger patients.

Participants with obesity or overweight lost up to 22.5% of their body weight with tirzepatide treatment.

Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.

Each weight-loss regimen had similar success in obesity management, regardless of patients reducing their calorie consumption through time-restricted eating or through calorie restriction alone.

Patients from the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of additional life expectancy, respectively.

The conference will take place in-person from from Friday, April 27 - Saturday, May 1 in Atlanta, Georgia and will feature both Proficiency and Masters tracks.

The prevalence of NAFLD in the pediatric population has increased in recent years.

A multi-disciplinary approach could help better manage obesity following bariatric surgery.

A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

The therapy is indicated for conditions associated with hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.

Alcohol use was additionally associated with worse fibrosis, but no interaction was noted between the two risk factors.

Rhythm Pharmaceuticals shares data from long-term extension study of setmelanotide in Bardet-Biedl Syndrome.

Data show LNCSBs as a substitute for sugar-sweetened beverages were associated with reduced body weight, BMI, percentage of body fat, and intrahepatocellular lipid.

A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

The estimated mean change in body weight from baseline to week 68 was -13.2% in the semaglutide 2.4 mg group versus -2.1% in the placebo group.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

A higher percentages of patients treated with tirzepatide had HbA1c less than 7% versus those treated with placebo (85%-90% versus 34%).

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.